Curis Inc - Company Profile
Powered by 
All the data and insights you need on Curis Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Curis Inc Strategy Report
- Understand Curis Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Curis Inc (Curis) is a biotechnology company that focuses on developing and commercializing novel drug candidates for treating cancers with substantial unmet medical need. The company’s lead product Erivedge has been developed in collaboration with F. Hoffmann-La Roche Ltd and Genentech, which is commercialized for the treatment of advanced basal cell carcinoma (BCC). The product is approved for use in patients with advanced BCC in the US, European Union (EU), Australia and several other countries. The company has four drug candidates in development, Fimepinostat (previously CUDC-907) for treating diffuse large B-cell lymphoma (DLBCL) and solid tumors; CA-170 for advanced solid tumors or lymphoma; CA-4948 for treating non-Hodgkin lymphomas, and CI-8993 a human IgG1 kappa monoclonal antibody directed against VISTA including PD-1 and PD-L1 for treatment of cancer. Curtis is headquartered in Lexington, Massachusetts, the US.
Headquarters
United States of America
Address
128 Spring Street, 4 Maguire Road, Lexington, Massachusetts, 02421
Website
www.curis.com
Telephone
1 617 5036500
No of Employees
48
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CRIS (NASD)
Revenue (2022)
$10.0M
-1.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
16.3%
(2022 vs 2021)
Market Cap*
$89.7M
Net Profit Margin (2022)
XYZ
15.2%
(2022 vs 2021)
* As of and is in US$
Curis Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Erivedge - Basal Cell Carcinoma | Erivedge |
| Pipeline | |
| Fimepinostat- MYC-altered diffuse large B-cell lymphoma/cancer | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In December, the company entered into an agreement with the University of Florida to investigate a drug known as emavusertib for people with advanced melanoma. |
| 2021 | Others | In December, the company was selected for addition to the Nasdaq Biotechnology Index and the iShares Biotechnology ETF. |
| 2021 | Regulatory Approval | In April, the company received Orphan Drug Designation for CA-4948 from the US FDA for the treatment of acute myeloid leukemia and myelodysplastic syndromes. |
Competitor Comparison
| Key Parameters | Curis Inc | F. Hoffmann-La Roche Ltd | Merck & Co Inc | Pfizer Inc | Bayer AG |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | United States of America | United States of America | Germany |
| City | Lexington | Basel | Kenilworth | New York | Leverkusen |
| State/Province | Massachusetts | - | New Jersey | New York | Nordrhein-Westfalen |
| No. of Employees | 48 | 103,605 | 72,000 | 88,000 | 99,723 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Martyn D. Greenacre | Chairman | Executive Board | 2000 | 81 |
| James E. Dentzer | Director; President; Chief Executive Officer | Executive Board | 2018 | 56 |
| Diantha Duvall | Chief Financial Officer | Senior Management | 2022 | 51 |
| Robert Martell, M.D., Ph.D. | Chief Scientific Officer | Senior Management | 2023 | 60 |
| Jonathan Zung, Ph.D. | Chief Development Officer | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward